Matthew R Meyer, Kristopher M Kirmess, Stephanie Eastwood, Traci L Wente-Roth, Faith Irvin, Mary S Holubasch, Venky Venkatesh, Ilana Fogelman, Mark Monane, Lucy Hanna, Gil D Rabinovici, Barry A Siegel, Rachel A Whitmer, Charles Apgar, Randall J Bateman, David M Holtzman, Michael Irizarry, David Verbel, Pallavi Sachdev, Satoshi Ito, John Contois, Kevin E Yarasheski, Joel B Braunstein, Philip B Verghese, Tim West
BACKGROUND: With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment. METHODS: High-throughput, mass spectrometry-based assays were used to measure %p-tau217 and amyloid beta (Aβ)42/40 ratio in blood samples from 583 individuals with suspected AD (53% positron emission tomography [PET] positive by Centiloid > 25)...
March 16, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association